Comparison · NCT04501679-99675e6c
Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nemolizumab vs Placebo: Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4. Trial comparisons, record NCT04501679-99675e6c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04501679-99675e6c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.372 | 0.305 | 0.444 | wilson | |
| Risk in group 2 | 0.0989 | 0.0529 | 0.177 | wilson | |
| Risk difference, group 1 minus group 2 | 0.273 | 0.17 | 0.358 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.76 | 1.97 | 7.18 | log | |
| Odds ratio, group 1 over group 2 | 5.39 | 2.54 | 11.4 | log | |
| Number needed to treat, for one more participant with the outcome on Nemolizumab than on Placebo | 3.67 | 2.79 | 5.89 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nemolizumab | Participants weighing \<90 kg received two SC injections of 30 mg nemolizumab (60 mg loading dose) at baseline then one SC injection Q4W. Participants weighing \>=90 kg received two SC injections of 30 mg nemolizumab (60 mg total) at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.~Nemolizumab: Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection. | 68 | 183 | OG000 |
| Group 2 | Placebo | Participants weighing \<90 kg received two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing \>=90 kg received two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.~Placebo: Participants received matching placebo as SC injection. | 9 | 91 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4
- Description
The SD NRS is a scale to be used by the participants to report the degree of their sleep loss related to PN. The baseline SD NRS was determined based on the average of daily SD NRS (score ranging from 0 to10) during the 7 days up to the treatment start (including until treatment start time) (rounding to nearest whole number is not permitted). A minimum of 4 daily scores out of the 7 days up to baseline study day is required for this calculation. On a scale of 0 to 10, with 0 being 'no sleep loss related to the symptoms of my skin disease (prurigo nodularis)' and 10 being 'I did not sleep at all due to the symptoms of prurigo nodularis'. Higher scores indicate worse outcome. Analysis window extension was applied to baseline, as described in the SAP. If a subject received any rescue therapy, the data at/after receipt of rescue therapy are considered as non-responders. Subjects with missing results are considered as non-responders.
- Time frame
- Baseline, Week 4
- Population
- ITT population consisted of all randomized participants.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- NCT number
- NCT04501679
- Phases
- PHASE3
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Lead sponsor
- Galderma R&D
- Results first posted
- 2024-07-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04501679?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04501679-99675e6c